Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy
- 1 October 2005
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (28), 6999-7004
- https://doi.org/10.1200/jco.2005.21.956
Abstract
Purpose To define the incidence, clinical features, and outcome to salvage chemotherapy in patients with late-relapse germ cell tumor (GCT) after a complete response to first-line chemotherapy. Patients and Methods Two patient populations were examined. First, retrospective analysis of 246 patients treated on a clinical trial with salvage chemotherapy was performed; 29 patients with late-relapse GCT were identified and evaluated for treatment outcome and survival. Salvage regimens included paclitaxel, ifosfamide, and cisplatin, single agents, or a high-dose chemotherapy program. Second, the incidence of late relapse was assessed by retrospective analysis of 551 patients after a complete response (CR) to first-line chemotherapy. Results Twenty-nine patients received salvage chemotherapy on a clinical trial for late relapse GCT. The median survival was 23.9 months. At a median follow-up of 50.6 months, there were nine survivors. The chemotherapy regimens varied, but the only CRs were observed in patients treated with paclitaxel, ifosfamide, and cisplatin. Seven (50%) of 14 patients treated with paclitaxel, ifosfamide, and cisplatin achieved a continuous CR. Among the second population of 551 patients who had previously achieved a CR to a first-line chemotherapy trial, 17 were identified as having a late relapse (3%). The median time to relapse for these 17 patients was 7.8 years. Conclusion Late-relapse GCT is uncommon and is associated with a poor prognosis resulting from a high degree of resistance to chemotherapy. Chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by surgery may be effective in patients with late-relapse GCT who are not considered candidates for primary surgery.This publication has 26 references indexed in Scilit:
- Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell TumorsJournal of Clinical Oncology, 2005
- High-Dose Chemotherapy as Initial Salvage Chemotherapy in Patients With Relapsed Testicular CancerJournal of Clinical Oncology, 2000
- Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell CancerJournal of Clinical Oncology, 2000
- Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.Journal of Clinical Oncology, 1998
- Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.Journal of Clinical Oncology, 1997
- Late relapse of testicular cancer.Journal of Clinical Oncology, 1995
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideThe New England Journal of Medicine, 1987
- VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.Journal of Clinical Oncology, 1986
- Late relapse of testicular cancer.Journal of Clinical Oncology, 1983
- Late Recurrence of Testicular TumorJournal of Urology, 1974